The SUNRAY-01 trial recruited its first UK patient this month at St James Hospital’s Leeds Cancer Centre and the NIHR Leeds Clinical Research Facility (CRF). SUNRAY-01 is a phase 3 global trial testing a treatment called olomorasib in metastatic non-small cell lung cancer (NSCLC).
Clinicians are studying if the addition of olomorasib alongside traditional treatment can improve outcomes for patients who have the KRAS G12C gene mutation, which is commonly associated with NSCLC.
Dr Katy Clarke, Consultant Thoracic Oncologist and Principal Investigator for SUNRAY-01, said: “It is a testament to the hard work of the whole team that we have the first UK participant in the SUNRAY-01 trial at Leeds Cancer Centre”.
“This trial is aimed at continuing the groundbreaking improvements in lung cancer survival we have seen over the last few years, and I believe this could be another practice changing trial.”
A big congratulations to our team at Leeds Cancer Centre and NIHR Leeds CRF for this achievement!
For the latest information on clinical trial participation, please visit/contact the SUNRAY 1 – Health Research Authority website.